Catalent, Inc. (NYSE:CTLT) Position Lessened by State of Alaska Department of Revenue

State of Alaska Department of Revenue reduced its stake in shares of Catalent, Inc. (NYSE:CTLTGet Rating) by 3.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,884 shares of the company’s stock after selling 850 shares during the period. State of Alaska Department of Revenue’s holdings in Catalent were worth $1,800,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of CTLT. CX Institutional bought a new position in Catalent during the second quarter valued at about $37,000. Clear Street Markets LLC grew its position in shares of Catalent by 408.1% in the second quarter. Clear Street Markets LLC now owns 376 shares of the company’s stock valued at $40,000 after purchasing an additional 302 shares during the last quarter. Selective Wealth Management Inc. acquired a new stake in shares of Catalent in the second quarter valued at about $57,000. Covestor Ltd grew its position in shares of Catalent by 84.9% in the first quarter. Covestor Ltd now owns 562 shares of the company’s stock valued at $62,000 after purchasing an additional 258 shares during the last quarter. Finally, Private Capital Group LLC grew its position in shares of Catalent by 62.6% in the second quarter. Private Capital Group LLC now owns 634 shares of the company’s stock valued at $68,000 after purchasing an additional 244 shares during the last quarter. 99.38% of the stock is currently owned by institutional investors.

Catalent Stock Up 2.2 %

NYSE:CTLT opened at $46.45 on Thursday. The stock’s fifty day moving average price is $46.36 and its two-hundred day moving average price is $78.04. Catalent, Inc. has a 52-week low of $40.69 and a 52-week high of $119.72. The company has a debt-to-equity ratio of 0.87, a quick ratio of 2.08 and a current ratio of 2.86. The company has a market cap of $8.36 billion, a price-to-earnings ratio of 19.85, a P/E/G ratio of 2.12 and a beta of 1.24.

Catalent (NYSE:CTLTGet Rating) last posted its quarterly earnings data on Tuesday, November 1st. The company reported $0.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.49 by ($0.24). Catalent had a return on equity of 12.55% and a net margin of 8.83%. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.06 billion. On average, analysts anticipate that Catalent, Inc. will post 2.93 EPS for the current year.

Insiders Place Their Bets

In other Catalent news, SVP Michael J. Grippo sold 2,451 shares of the company’s stock in a transaction on Monday, October 31st. The shares were sold at an average price of $65.83, for a total transaction of $161,349.33. Following the completion of the sale, the senior vice president now owns 17,792 shares in the company, valued at approximately $1,171,247.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Catalent news, SVP Michael J. Grippo sold 2,451 shares of the company’s stock in a transaction on Monday, October 31st. The shares were sold at an average price of $65.83, for a total transaction of $161,349.33. Following the completion of the sale, the senior vice president now owns 17,792 shares in the company, valued at approximately $1,171,247.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Thomas W. Hawkeswood sold 930 shares of the company’s stock in a transaction on Monday, October 10th. The shares were sold at an average price of $77.46, for a total transaction of $72,037.80. Following the sale, the insider now owns 5,364 shares of the company’s stock, valued at approximately $415,495.44. The disclosure for this sale can be found here. In the last quarter, insiders have sold 4,161 shares of company stock valued at $273,713. 0.58% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on CTLT shares. Bank of America downgraded Catalent from a “buy” rating to a “neutral” rating and lowered their price target for the company from $125.00 to $60.00 in a research report on Wednesday, November 2nd. Barclays lowered their price target on Catalent from $105.00 to $62.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 2nd. StockNews.com downgraded Catalent from a “hold” rating to a “sell” rating in a research report on Saturday, November 5th. TheStreet downgraded Catalent from a “b-” rating to a “c+” rating in a report on Friday, October 28th. Finally, KeyCorp decreased their price objective on Catalent from $125.00 to $85.00 and set an “overweight” rating on the stock in a report on Wednesday, November 2nd. One analyst has rated the stock with a sell rating, three have given a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $92.80.

Catalent Profile

(Get Rating)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.

See Also

Want to see what other hedge funds are holding CTLT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalent, Inc. (NYSE:CTLTGet Rating).

Institutional Ownership by Quarter for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.